Compare Lionsgate Studios Corp Common Shares (LION) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lionsgate Studios Corp Common Shares vs Relay Therapeutics Inc. Common Stock — how do they compare? Lionsgate Studios Corp Common Shares trades at $10.89 (market cap $3.24B), while Relay Therapeutics Inc. Common Stock trades at $17.13 (market cap $3.74B). The key difference: Relay Therapeutics Inc. Common Stock is the larger of the two by market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Lionsgate Studios Corp Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lionsgate Studios Corp Common Shares for 0 Days and Relay Therapeutics Inc. Common Stock for 5 Days on average.
| LION | RLAY | |
|---|---|---|
Market Cap | $3.24B | $3.74B |
Volume | 3,214,595 | 2,936,788 |
Sector | Technology | Health |
52-Week High | $16.40 | $20.75 |
52-Week Low | $5.91 | $6.05 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $6.75B | $2.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.
The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.
Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.
Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lionsgate Studios Corp Common Shares
Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.
Read more on LION →About Relay Therapeutics Inc. Common Stock
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →
